Moberg Pharma AB (publ) Total Assets
Moberg Pharma AB (publ) total assets. Based on the latest financial reports, Moberg Pharma AB (publ) (MOB) holds total assets worth Skr682.26 Million SEK (≈ $73.42 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Moberg Pharma AB (publ) for the company's overall valuation and market capitalisation.
Total Assets of Moberg Pharma AB (publ) (2008–2025)
Total assets of Moberg Pharma AB (publ) from 2008 to 2025. This chart illustrates how Moberg Pharma AB (publ)'s total assets have evolved over time, based on quarterly financial data. See latest Moberg Pharma AB (publ) stock price today for real-time trading data and today's change.
Moberg Pharma AB (publ) - Asset Composition Analysis
Moberg Pharma AB (publ) Total Assets Breakdown (December 2025)
Moberg Pharma AB (publ) total assets breakdown as of December 2025. Moberg Pharma AB (publ)'s total assets of Skr682.26 Million consist of 34.9% current assets and 65.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr28.33 Million | 33.9% |
| Accounts Receivable | Skr3.38 Million | 0.5% |
| Inventory | Skr3.58 Million | 0.5% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr348.96 Million | 51.2% |
| Goodwill | Skr142.73 Million | 20.9% |
Asset Composition Trend (2008–2025)
This chart illustrates how Moberg Pharma AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Moberg Pharma AB (publ) working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Moberg Pharma AB (publ)'s current assets represent 34.9% of total assets in 2025, a decrease from 96.6% in 2008.
- Cash Position: Cash and equivalents constituted 33.9% of total assets in 2025, down from 89.5% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 71.0% of total assets, an increase from 5.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 51.2% of total assets.
Moberg Pharma AB (publ) Competitors by Total Assets
Key competitors of Moberg Pharma AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
Moberg Pharma AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.71 | 17.95 | 10.35 |
| Quick Ratio | 14.49 | 17.69 | 11.11 |
| Cash Ratio | 1.75 | 2.09 | 6.64 |
| Working Capital | Skr221.74 Million | Skr283.39 Million | Skr130.31 Million |
Moberg Pharma AB (publ) - Advanced Valuation Insights
This section examines the relationship between Moberg Pharma AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.76 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -3.4% |
| Total Assets | Skr682.26 Million |
| Market Capitalization | $54.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Moberg Pharma AB (publ)'s assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Moberg Pharma AB (publ)'s assets decreased by 3.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Moberg Pharma AB (publ) (2008–2025)
The table below shows the annual total assets of Moberg Pharma AB (publ) from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr682.26 Million ≈ $73.42 Million |
-3.37% |
| 2024-12-31 | Skr706.09 Million ≈ $75.99 Million |
+11.24% |
| 2023-12-31 | Skr634.73 Million ≈ $68.31 Million |
+12.46% |
| 2022-12-31 | Skr564.42 Million ≈ $60.74 Million |
+25.18% |
| 2021-12-31 | Skr450.89 Million ≈ $48.52 Million |
-6.18% |
| 2020-12-31 | Skr480.58 Million ≈ $51.72 Million |
+268.00% |
| 2019-12-31 | Skr130.59 Million ≈ $14.05 Million |
-89.57% |
| 2018-12-31 | Skr1.25 Billion ≈ $134.69 Million |
+2.32% |
| 2017-12-31 | Skr1.22 Billion ≈ $131.64 Million |
-0.72% |
| 2016-12-31 | Skr1.23 Billion ≈ $132.60 Million |
+210.02% |
| 2015-12-31 | Skr397.45 Million ≈ $42.77 Million |
+10.49% |
| 2014-12-31 | Skr359.72 Million ≈ $38.71 Million |
+32.44% |
| 2013-12-31 | Skr271.61 Million ≈ $29.23 Million |
-3.26% |
| 2012-12-31 | Skr280.76 Million ≈ $30.21 Million |
+203.68% |
| 2011-12-31 | Skr92.45 Million ≈ $9.95 Million |
+646.64% |
| 2010-12-31 | Skr12.38 Million ≈ $1.33 Million |
-64.92% |
| 2009-12-31 | Skr35.30 Million ≈ $3.80 Million |
+56.28% |
| 2008-12-31 | Skr22.59 Million ≈ $2.43 Million |
-- |
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.